FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* WAREHAM JOHN P						2. Issuer Name and Ticker or Trading Symbol STERIS CORP [STE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
															X Directo Officer	or (give title	10% Owner Other (speci				
(Last) (First) (Middle) C/O 5960 HEISLEY ROAD						3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015									below)			below)	орсону		
						Ame	endmer	nt, Date	of Original	ndividual or (Joint/Group	Filin	g (Check Ap	plicable							
(Street) MENTOR OH 44060															X Form f	iled by Moi	e Reporting Person re than One Reporti				
(City) (State) (Zip)															reisui	ı					
		Tab	le I - Nor	ı-Deriv	ative	Se	curiti	ies Ad	quired,	Dis	posed c	of, or B	enef	iciall	y Owned	l				ĺ	
				2. Transaction Date (Month/Day/Year)		ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)					es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or F	Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)		
Common Shares, No Par Value				11/02	2/2015				D		31,56	60 I)	(1)		0		D			
		ī	able II -						uired, D s, option						Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr 8)		n of E		6. Date Exercisable Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or	ount nber ires							
Director Stock Option (right to buy)	\$31.61	11/02/2015			D			4,995	(2)	0	8/03/2021	Common Shares, No Par Value		995	(2)	0		D			
Director Stock Option (right to buy)	\$32.36	11/02/2015			D			5,150	(3)	0	8/03/2022	Common Shares, No Par Value		150	(3)	0		D			
Director Stock Option (right to buy)	\$43.92	11/02/2015			D			6,727	(4)	0	8/08/2023	Common Shares, No Par Value		727	(4)	0		D			
Director Stock Option (right to buy)	\$51.53	11/02/2015			D			6,622	(5)	0	8/06/2024	Common Shares, No Par Value		622	(5)	0		D		_	
Director Stock									(6)	T	0 10 4 10 00 =	Common Shares,		226	(6)						

Explanation of Responses:

\$64.05

(7)

11/02/2015

11/02/2015

Option

buy) Career

Stock

Units

(right to

Restricted

1. Represents shares of STERIS Corporation ("STERIS") disposed of pursuant to merger of a wholly-owned subsidiary of STERIS plc ("New STERIS") with and into STERIS, with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for ordinary shares of New STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.

(6)

(7)

08/31/2025

(7)

5,936

5,633

D

5,936

5,633

No Par

Value

Common

Shares

No Par

Value

(6)

\$0.00

0

0

D

D

- 2. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 4,995 ordinary shares of New STERIS for \$31.61 per share, subject to the same terms and conditions that were applicable to the original STERIS option.
- 3. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 5,150 ordinary shares of New STERIS for \$32.36 per share, subject to the same terms and conditions that were applicable to the original STERIS option.
- 4. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 6,727 ordinary shares of New STERIS for \$43.92 per share, subject to the same terms and conditions that were applicable to the original STERIS option.
- 5. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 6,622 ordinary shares of New STERIS for \$51.53 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

6. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 5,936 ordinary shares of New STERIS for \$64.05 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

7. At the effective time of the Merger, each STERIS career restricted stock unit was cancelled and converted to a New STERIS career restricted stock unit, subject to the same terms and conditions that were applicable to the original STERIS career restricted stock unit. These New STERIS career restricted stock units are fully vested and will be settled in New STERIS ordinary shares six months after the cessation of the Director's Board service.

Remarks:

/s/ Dennis P. Patton,
Authorized Representative under Power of Attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.